Identification of candidate biomarkers with cancer‐specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis

Identification of candidate biomarkers with cancer‐specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis
复制标题

DOI：
10.1002/prca.201090032
复制
发表时间：
2010-09
期刊：
PROTEOMICS – Clinical Applications
影响因子：
--
通讯作者：
K. Abbott;Jae-Min Lim;L. Wells;B. Benigno;J. McDonald;M. Pierce
K. Abbott;Jae-Min Lim;L. Wells;B. Benigno;J. McDonald;M. Pierce
中科院分区：
其他
文献类型：
--
作者：
K. Abbott;Jae-Min Lim;L. Wells;B. Benigno;J. McDonald;M. Pierce

文献摘要

被引文献

相似文献

当肿瘤局限于卵巢时，上皮性卵巢癌的诊断率低于25%，导致5年生存率低于30%。因此，迫切需要对卵巢癌进行早期诊断。我们对子宫内膜样卵巢癌组织和正常卵巢组织的糖转录组进行了比较分析，发现参与N -连锁糖基化的一组限制性糖基转移酶的转录本存在明显差异。利用与多糖结构结合的凝集素预测显示变化，我们观察到凝集素结合的糖蛋白的差异与一些转录物的差异一致。在这项研究中，我们通过使用选定的凝集素扩展了我们的观察，对卵巢癌和正常卵巢组织进行了靶向糖蛋白组学分析。我们的研究结果已经确定了几种显示肿瘤特异性糖基化变化的糖蛋白。我们已经验证了这些糖基化的变化，从组织使用免疫沉淀和凝集素印迹检测。然后使用从良性卵巢腺瘤、交界性卵巢腺癌和恶性卵巢腺癌中获得的现有微阵列数据进一步分析验证的糖蛋白。在微阵列数据集中发现表达高于对照水平的验证糖蛋白，然后筛选卵巢癌患者血清中肿瘤特异性聚糖修饰。从这两种糖蛋白标记物（骨膜蛋白和血栓反应蛋白）中获得的结果证实，肿瘤特异性聚糖变化可用于区分卵巢癌患者血清和正常血清。
Epithelial ovarian cancer is diagnosed less than 25% of the time when the cancer is confined to the ovary, leading to 5‐year survival rates of less than 30%. Therefore, there is an urgent need for early diagnostics for ovarian cancer. Our study using glycotranscriptome comparative analysis of endometrioid ovarian cancer tissue and normal ovarian tissue led to the identification of distinct differences in the transcripts of a restricted set of glycosyltransferases involved in N‐linked glycosylation. Utilizing lectins that bind to glycan structures predicted to show changes, we observed differences in lectin‐bound glycoproteins consistent with some of the transcript differences. In this study, we have extended our observations by the use of selected lectins to perform a targeted glycoproteomic analysis of ovarian cancer and normal ovarian tissues. Our results have identified several glycoproteins that display tumor‐specific glycosylation changes. We have verified these glycosylation changes on glycoproteins from tissue using immunoprecipitation followed by lectin blot detection. The glycoproteins that were verified were then analyzed further using existing microarray data obtained from benign ovarian adenomas, borderline ovarian adenocarcinomas, and malignant ovarian adenocarcinomas. The verified glycoproteins found to be expressed above control levels in the microarray data sets were then screened for tumor‐specific glycan modifications in serum from ovarian cancer patients. Results obtained from two of these glycoprotein markers, periostin and thrombospondin, have confirmed that tumor‐specific glycan changes can be used to distinguish ovarian cancer patient serum from normal serum.